| Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features CJ Creighton, X Li, M Landis, JM Dixon, VM Neumeister, A Sjolund, ... Proceedings of the National Academy of Sciences 106 (33), 13820-13825, 2009 | 1613 | 2009 |
| A standard curve based method for relative real time PCR data processing A Larionov, A Krause, W Miller BMC bioinformatics 6, 1-16, 2005 | 1069 | 2005 |
| Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours VAL Tomlinson, HJ Newbery, NR Wray, J Jackson, A Larionov, WR Miller, ... BMC cancer 5, 1-7, 2005 | 197 | 2005 |
| Molecular response to aromatase inhibitor treatment in primary breast cancer A Mackay, A Urruticoechea, JM Dixon, T Dexter, K Fenwick, A Ashworth, ... Breast Cancer Research 9, 1-14, 2007 | 134 | 2007 |
| Accurate prediction and validation of response to endocrine therapy in breast cancer AK Turnbull, LM Arthur, L Renshaw, AA Larionov, C Kay, AK Dunbier, ... Journal of Clinical Oncology 33 (20), 2270-2278, 2015 | 128 | 2015 |
| The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers R Hrstka, R Nenutil, A Fourtouna, MM Maslon, C Naughton, S Langdon, ... Oncogene 29 (34), 4838-4847, 2010 | 127 | 2010 |
| Understanding the mechanisms of aromatase inhibitor resistance WR Miller, AA Larionov Breast Cancer Research 14, 1-11, 2012 | 121 | 2012 |
| Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole WR Miller, A Larionov, L Renshaw, TJ Anderson, JR Walker, A Krause, ... J Clin Oncol 27 (9), 1382-1387, 2009 | 119 | 2009 |
| Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole WR Miller, AA Larionov, L Renshaw, TJ Anderson, S White, J Murray, ... Pharmacogenetics and genomics 17 (10), 813-826, 2007 | 113 | 2007 |
| Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study E Fewings, A Larionov, J Redman, MA Goldgraben, J Scarth, ... The lancet Gastroenterology & hepatology 3 (7), 489-498, 2018 | 108 | 2018 |
| High prevalence and breast cancer predisposing role of the BLM c. 1642 C> T (Q548X) mutation in Russia AP Sokolenko, AG Iyevleva, EV Preobrazhenskaya, NV Mitiushkina, ... International Journal of Cancer 130 (12), 2867-2873, 2012 | 105 | 2012 |
| Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole WR Miller, A Larionov Breast cancer research 12, 1-9, 2010 | 95 | 2010 |
| Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients AA Larionov Frontiers in oncology 8, 89, 2018 | 89 | 2018 |
| Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects L Berstein, S Maximov, E Gershfeld, I Meshkova, V Gamajunova, ... European Journal of Obstetrics & Gynecology and Reproductive Biology 105 (2 …, 2002 | 88 | 2002 |
| Aromatase in skeletal muscle AA Larionov, DA Vasyliev, JI Mason, AF Howie, LM Berstein, WR Miller The Journal of steroid biochemistry and molecular biology 84 (4), 485-492, 2003 | 82 | 2003 |
| Direct integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis AK Turnbull, RR Kitchen, AA Larionov, L Renshaw, JM Dixon, AH Sims BMC medical genomics 5, 1-11, 2012 | 66 | 2012 |
| Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole WR Miller, A Larionov, TJ Anderson, DB Evans, JM Dixon The pharmacogenomics journal 12 (1), 10-21, 2012 | 58 | 2012 |
| Challenges in defining predictive markers for response to endocrine therapy in breast cancer AA Larionov, WR Miller Future oncology 5 (9), 1415-1428, 2009 | 47 | 2009 |
| Molecular changes in lobular breast cancers in response to endocrine therapy LM Arthur, AK Turnbull, VL Webber, AA Larionov, L Renshaw, C Kay, ... Cancer research 74 (19), 5371-5376, 2014 | 38 | 2014 |
| High prevalence of GPRC5A germline mutations in BRCA1‐mutant breast cancer patients AP Sokolenko, DR Bulanova, AG Iyevleva, SN Aleksakhina, ... International journal of cancer 134 (10), 2352-2358, 2014 | 38 | 2014 |
